|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1240 USD | +22.77% |
|
+6.90% | -7.19% |
Company Valuation: ZyVersa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Market Cap 1 | 14.26 | 4.719 | 2.659 | 1.082 |
| Change | - | -66.9% | -43.66% | -59.32% |
| Enterprise Value (EV) 1 | 8.465 | 1.59 | 1.128 | 0.9798 |
| Change | - | -81.22% | -29.07% | -13.12% |
| P/E | -2.6x | -0.01x | -0.12x | -0.03x |
| PBR | 0.15x | 0.33x | 0.31x | -0.09x |
| PEG | -0x | -0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -0.73x | -0.11x | -0.12x | -0.14x |
| EV / EBIT | -0.72x | -0.11x | -0.12x | -0.14x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -211.2 | -1,090 | -8.48 | -4.184 |
| Distribution rate | - | - | - | - |
| Net sales | - | - | - | - |
| EBITDA 1 | -11.67 | -14.41 | -9.13 | -6.838 |
| EBIT 1 | -11.68 | -14.42 | -9.137 | -6.845 |
| Net income 1 | -14.12 | -98.3 | -9.413 | -24.95 |
| Net Debt 1 | -5.793 | -3.129 | -1.531 | -0.1018 |
| Reference price 2 | 549.5005 | 9.0000 | 1.0600 | 0.1336 |
| Nbr of stocks (in thousands) | 25.9 | 524 | 2,508 | 8,096 |
| Announcement Date | 3/31/23 | 3/25/24 | 3/27/25 | 3/31/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 818K | ||
| 21.25x | 6.51x | 14.24x | 1.5% | 56.54B | ||
| 31.6x | 7.8x | 24.02x | 0.05% | 53.6B | ||
| -17.91x | 4.18x | -7.32x | -.--% | 22.91B | ||
| -38.06x | 12.21x | -36.05x | -.--% | 21.37B | ||
| 25.45x | 4.98x | 13.18x | -.--% | 20.27B | ||
| 24.28x | 4.73x | 15.36x | -.--% | 17.56B | ||
| -737.38x | 35.03x | -3943.97x | -.--% | 14.75B | ||
| 40.7x | 16.37x | 42.16x | 0.09% | 13.53B | ||
| 16.73x | 4.82x | 11.24x | -.--% | 13.33B | ||
| Average | -70.37x | 10.74x | -429.68x | 0.18% | 23.39B | |
| Weighted average by Cap. | -32.01x | 9.11x | -238.39x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ZVSA Stock
- Valuation ZyVersa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















